Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2015

01-06-2015 | Position Statement/Guideline

Italian Association of Clinical Endocrinologists (AME) & Italian Association of Clinical Diabetologists (AMD) Position Statement

Diabetes mellitus and thyroid disorders: recommendations for clinical practice

Authors: Edoardo Guastamacchia, Vincenzo Triggiani, Alberto Aglialoro, Antimo Aiello, Lucia Ianni, Mauro Maccario, Michele Zini, Carlo Giorda, Rinaldo Guglielmi, Corrado Betterle, Roberto Attanasio, Giorgio Borretta, Piernicola Garofalo, Enrico Papini, Roberto Castello, Antonio Ceriello

Published in: Endocrine | Issue 2/2015

Login to get access

Abstract

Thyroid disease and diabetes mellitus, the most common disorders in endocrine practice, are not infrequently associated in the same subject. An altered thyroid function may affect glucose tolerance and worsen metabolic control in patients with diabetes. Thyrotoxicosis increases the risk of hyperglycemic emergencies, while a clinically relevant hypothyroidism may have a detrimental effect on glycemic control in diabetic patients. The association of alterations in thyroid function with diabetes mellitus may adversely affect the risk of cardiovascular and microvascular complications resulting from diabetes. Moreover, the treatments used for both diabetes and thyroid disease, respectively, can impact one other. Finally, multinodular goiter, but not thyroid carcinoma, was shown to be more prevalent in type 2 diabetes mellitus. Aim of the present Position Statement is to focus on the evidence concerning the association of thyroid disease and diabetes mellitus and to provide some practical suggestions for an updated clinical management.
Literature
1.
2.
D. Atkins, D. Best, P.A. Briss, M. Eccles, Y. Falck-Ytter, S. Flottorp, G.H. Guyatt, R.T. Harbour, M.C. Haugh, D. Henry, S. Hill, R. Jaeschke, G. Leng, A. Liberati, N. Magrini, J. Mason, P. Middleton, J. Mrukowicz, D. O’Connell, A.D. Oxman, B. Phillips, H.J. Schünemann, T. Edejer, H. Varonen, G.E. Vist, J.W. Williams Jr, S. Zaza, GRADE Working Group, Grading quality of evidence and strength of recommendations. BMJ 328(7454), 1490 (2004). (no LoE)PubMed
3.
B.A. Swiglo, M.H. Murad, H.J. Schünemann, R. Kunz, R.A. Vigersky, G.H. Guyatt, V.M. Montori, A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93(3), 666–673 (2008). doi:10.​1210/​jc.​2007-1907. (no LoE)PubMed
4.
G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, H.J. Schünemann, GRADE Working Group, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650), 924–926 (2008). doi:10.​1136/​bmj.​39489.​470347.​AD. (no LoE)PubMedCentralPubMed
5.
J.I. Mechanick, P.M. Camacho, R.H. Cobin, A.J. Garber, J.R. Garber, H. Gharib, S.M. Petak, H.W. Rodbard, D.L. Trence, American Association of Clinical Endocrinologists, Protocol for standardized production of clinical practice guidelines-2010 update. Endocr. Pract. 16(2), 270–283 (2010). (no LoE)PubMed
6.
M.P.J. Vanderpump, The epidemiology of thyroid diseases, in Werner and Ingbar’s the thryoid: a fundamental and clinical text, ed. by L.E. Braverman, R.D. Utiger (J.B. Lippicott-Raven, Philadelphia, 2005), pp. 398–496
7.
F. Aghini-Lombardi, L. Antonangeli, E. Martino, P. Vitti, D. Maccherini, F. Leoli, T. Rago, L. Grasso, R. Valeriano, A. Balestrieri, A. Pinchera, The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin. Endocrinol. Metab. 84(2), 561–566 (1999). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
8.
W.M. Tunbridge, D.C. Evered, R. Hall, D. Appleton, M. Brewis, F. Clark, J.G. Evans, E. Young, T. Bird, P.A. Smith, The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol. (Oxford) 7(6), 481–493 (1977). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
9.
M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, J. Grimley Evans, D.M. Hasan, H. Rodgers, F. Tunbridge, E.T. Young, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxford) 43(1), 55–68 (1995). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
10.
J.V. Parle, J.A. Franklyn, K.W. Cross, S.C. Jones, M.C. Sheppard, Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin. Endocrinol. (Oxford) 34(1), 77–83 (1991). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
11.
12.
M. Mouradian, N. Abourizk, Diabetes mellitus and thyroid disease. Diabetes Care 6(5), 512–520 (1983). (no LoE)PubMed
13.
R.S. Gray, W.J. Irvine, B.F. Clarke, Screening for thyroid dysfunction in diabetics. Br. Med. J. 2(6202), 1439 (1979). (no LoE)PubMedCentralPubMed
14.
15.
16.
P. Perros, R.J. McCrimmon, G. Shaw, B.M. Frier, Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet. Med. 12(7), 622–627 (1995)PubMed
17.
G.E. Umpierrez, K.A. Latif, M.B. Murphy, H.C. Lambeth, F. Stentz, A. Bush, A.E. Kitabch, Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care 26(4), 1181–1185 (2003). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
18.
L.C. de Graaff, J.W. Smit, J.K. Radder, Prevalence and clinical significance of organ-specific autoantibodies in type 1 diabetes mellitus. Neth. J. Med. 65(7), 235–247 (2007). (no LoE)PubMed
19.
J.M. Moore, J.M. Neilson, Antibodies to gastric mucosa and thyroid in diabetes mellitus. Lancet. 2(7309), 645–647 (1963). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
20.
D.E. Goldstein, A. Drasch, J. Gibbs, R.M. Blizzard, Diabetes mellitus: the incidence of circulating antibodies against thyroid, gastric, and adrenal tissue. J. Pediatr. 77(2), 304–306 (1970). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
21.
W.J. Irvine, B.F. Clarke, L. Scarth, D.R. Cullen, L.J. Duncan, Thyroid and gastric autoimmunity in patients with diabetes mellitus. Lancet 2(7665), 163–168 (1970)PubMed
22.
J. Nerup, C. Binder, Thyroid, gastric and adrenal auto-immunity in diabetes mellitus. Acta. Endocrinol. (Copenh) 72(2), 279–286 (1973). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
23.
M. Neufeld, N.K. Maclaren, W.J. Riley, D. Lezotte, J.V. McLaughlin, J. Silverstein, A.L. Rosenbloom, Islet cell and other organ-specific antibodies in U.S. Caucasians and Blacks with insulin-dependent diabetes mellitus. Diabetes 29(8), 589–592 (1980). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
24.
W.J. Riley, N.K. Maclaren, D.C. Lezotte, R.P. Spillar, A.L. Rosenbloom, Thyroid autoimmunity in insulin-dependent diabetes mellitus: the case for routine screening. J. Pediatr. 99(3), 350–354 (1981). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
25.
S. Court, J.M. Parkin, Hypothyroidism and growth failure in diabetes mellitus. Arch. Dis. Child. 57, 622–624 (1982). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMedCentralPubMed
26.
J. Kokkonen, J. Kiuttu, A. Mustonen, O. Räsänen, Organ-specific antibodies in healthy and diabetic children and young adults. Acta. Pediatr. Scand. 71(2), 223–226 (1982). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
27.
B.B. Gilani, M.H. MacGillivray, M.L. Voorhess, B.J. Mills, W.J. Riley, N.K. MacLaren, Thyroid hormone abnormalities at diagnosis of insulin-dependent diabetes mellitus in children. J. Pediatr. 105(2), 218–222 (1984). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
28.
N.K. Maclaren, W.J. Riley, Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus. Diabetes Care 8(Suppl 1), 34–38 (1985). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
29.
D.W. Drell, A.L. Notkins, Multiple immunological abnormalities in patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 30(3), 132–143 (1987). (no LoE)PubMed
30.
S. Kontiainen, A. Schlenzka, S. Koskimies, A. Rilva, J. Mäenpää, Autoantibodies and autoimmune diseases in young diabetics. Diabetes Res. 13(4), 151–156 (1990). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
31.
M. Landin-Olsson, F.A. Karlsson, A. Lernmark, G. Sundkvist, Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden. Diabetes 41(8), 1022–1027 (1992). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
32.
G. Radetti, C. Paganini, L. Gentili, S. Bernasconi, C. Betterle, M. Borkenstein, K. Cvijovic, M. Kadrnka-Lovrencic, C. Krzisnik, T. Battelino, R. Lorini, S. Marinoni, F. Rigon, L. Tatò, L. Pinelli, G. Tonini, Frequency of Hashimoto’s thyroiditis in children with type 1 diabetes mellitus. Acta Diabetol. 32(2), 121–124 (1995). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif ) doi:10.​1007/​BF00569570 PubMed
33.
P. Abrams, I. De Leeuw, J. Vertommen, In new-onset insulin-dependent diabetic patients the presence of anti-thyroid peroxidase antibodies is associated with islet cell autoimmunity and the high risk haplotype HLA DQA1*0301-DQB1*0302. Belgian Diabetes Registry. Diabet. Med. 13(5), 415–419 (1996). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
34.
I.G. Jefferson, The clinical approach to thyroid disorders associated with childhood insulin dependent diabetes mellitus. J. Pediatr. Endocrinol. Metab. 9(Suppl 1), 95–100 (1996). (no LoE)PubMed
35.
R. Lorini, G. d’Annunzio, L. Vitali, A. Scaramuzza, IDDM and autoimmune thyroid disease in the pediatric age group. J. Pediatr. Endocrinol. Metab. 9(Suppl 1), 89–94 (1996). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
36.
F. Presotto, C. Betterle, Insulin-dependent diabetes mellitus: a constellation of autoimmune diseases. J. Pediatr. Endocrinol. Metab. 10(5), 455–469 (1997). (no LoE)PubMed
37.
E. McCanlies, L.A. O’Leary, T.P. Foley, M.K. Kramer, J.P. Burke, A. Libman, J.S. Swan, A.R. Steenkiste, B.J. Mccarthy, M. Trucco, J.S. Dorman, Hashimoto’s thyroiditis and insulin-dependent diabetes mellitus: differences among individuals with and without abnormal thyroid function. J. Clin. Endocrinol. Metab. 83(5), 1548–1551 (1998). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
38.
C.C. Chang, C.N. Huang, L.M. Chuang, Autoantibodies to thyroid peroxidase in patients with type 1 diabetes in Taiwan. Eur. J. Endocrinol. 139(1), 44–48 (1998). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
39.
D. Hansen, F.N. Bennedbaek, L.K. Hansen, M. Hoier-Madsen, B.B. Jacobsen, L. Hegedüs, Thyroid function, morphology and autoimmunity in young patients with insulin-dependent diabetes mellitus. Eur. J. Endocrinol. 140(6), 512–518 (1999). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
40.
M.B. Roldán, M. Alonso, R. Barrio, Thyroid autoimmunity in children and adolescents with Type 1 diabetes mellitus. Diabetes Nutr. Metab. 12(1), 27–31 (1999). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
41.
G. Gambelunghe, F. Forini, S. Laureti, G. Murdolo, G. Toraldo, F. Santeusanio, P. Brunetti, C.B. Sanjeevi, A. Falorni, Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin. Endocrinol. (Oxford) 52(5), 565–573 (2000). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
42.
C. Rattarasarn, M.A. Diosdado, J. Ortego, R. Leelawattana, S. Soonthornpun, W. Setasuban, S. Jaruratanasirikul, N. Patarakijvanich, Thyroid autoantibodies in Thai type 1 diabetic patients: clinical significance and their relationship with glutamic acid decarboxylase antibodies. Diabetes Res. Clin. Pract. 49(2–3), 107–111 (2000). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
43.
C.E. De Block, I.H. De Leeuw, J.J. Vertommen, R.P. Rooman, M.V. Du Caju, C.M. Van Campenhout, J.J. Weyler, F. Winnock, J. Van Autreve, F.K. Gorus, Belgian Diabetes Registry, Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clin. Exp. Immunol. 126(2), 236–241 (2001). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
44.
O. Kordonouri, A. Klinghammer, E.B. Lang, A. Grüters-Kieslich, M. Grabert, R.W. Holl, Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care 25(8), 1346–1350 (2002). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
45.
H. Bárová, J. Perusicová, M. Hill, I. Sterzl, K. Vondra, Z. Masek, Anti-GAD-positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiol. Res. 53(3), 279–286 (2004). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
46.
M. Prázný, J. Skrha, Z. Límanová, Z. Vanícková, J. Hilgertová, J. Prázná, M. Jaresová, I. Stríz, Screening for associated autoimmunity in type 1 diabetes mellitus with respect to diabetes control. Physiol. Res. 54(1), 41–48 (2005). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
47.
K. Vondra, J. Vrbíková, B. Bendlová, K. Dvorakova, I. Sterzl, M. Vondrova, Differences in type I diabetes mellitus of young adults with and without thyroid autoimmunity. Exp. Clin. Endocrinol. Diabetes 113(7), 404–408 (2005). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
48.
J.M. Barker, J. Yu, L. Yu, J. Wang, D. Miao, F. Bao, E. Hoffenberg, J.C. Nelson, P.A. Gottlieb, M. Rewers, G.S. Eisenbarth, Autoantibody “subspecificity” in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care 28(4), 850–855 (2005). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
49.
H. Völzke, U. Krohn, H. Wallaschofski, J. Lüdemann, U. John, W. Kerner, The spectrum of thyroid disorders in adult type 1 diabetes mellitus. Diabetes Metab. Res. Rev. 23(3), 227–233 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
50.
R.M. Mantovani, L.M. Mantovani, V.M. Dias, Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus: prevalence and risk factors. J. Pediatr. Endocrinol. Metab. 20(6), 669–675 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
51.
K. Warncke, E.E. Fröhlich-Reiterer, A. Thon, S.E. Hofer, D. Wiemann, R.W. Holl, DPV Initiative of the German Working Group for Pediatric Diabetology, German BMBF Competence Network for Diabetes Mellitus, DPV Initiative of the German Working Group for Pediatric Diabetology, German BMBF Competence Network for Diabetes Mellitus, Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28,671 patients from the German/Austrian DPV-Wiss database. Diabetes Care 33(9), 2010–2012 (2010). doi:10.​2337/​dc10-0404 PubMedCentralPubMed
52.
R. Volpé, Autoimmunity in the Endocrine System, in Monographs on Endocrinology (Springer-Verlag, Berlin-Heidelberg-New York, (1981)), pp. 19–111. (no LoE)
53.
D. Maugendre, F. Vérité, I. Guilhem, B. Genetet, H. Allannic, M. Delamaire, Anti-pancreatic autoimmunity and Graves’ disease: study of a cohort of 600 Caucasian patients. Eur. J. Endocrinol. 137(5), 503–510 (1997). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
54.
R. Kalmann, M.P. Mourits, Diabetes mellitus: a risk factor in patients with Graves’ orbitopathy. Br. J. Ophthalmol. 83(4), 463–465 (1999). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMedCentralPubMed
55.
W.J. Irvine, C.J. McCallum, R.S. Gray, C.J. Campbell, L.J. Duncan, J.W. Farquhar, H. Vaughan, P.J. Morris, Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes coexistent autoimmune disease, and HLA type. Diabetes 26(2), 138–147 (1977). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
56.
G.M. Bright, R.M. Blizzard, D.L. Kaiser, W.L. Clarke, Organ-specific autoantibodies in children with common endocrine diseases. J. Pediatr. 100(1), 8–14 (1982). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
57.
C. Betterle, F. Presotto, B. Pedini, L. Moro, R.S. Slack, F. Zanette, R. Zanchetta, Islet cell and insulin autoantibodies in organ-specific autoimmune patients. Their behaviour and predictive value in the development of type 1 (insulin-dependent) diabetes mellitus. A ten year follow-up study. Diabetologia 30(5), 292–297 (1987). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
58.
Y. Yamaguchi, N. Chikuba, Y. Ueda, H. Yamamoto, H. Yamasaki, T. Nakanishi, S. Akazawa, S. Nagataki, Islet cell antibodies in patients with autoimmune thyroid diseases. Diabetes 40(3), 319–322 (1991). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
59.
C. Betterle, F. Presotto, L. Magrin, B. Pedini, L. Moro, A. Caretto, R. Zanchetta, The natural history of pre-type 1 (insulin-dependent) diabetes mellitus in patients with autoimmune endocrine diseases. Diabetologia 37(1), 95–103 (1994). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
60.
B. Hallengren, A. Falorni, M. Landin-Olsson, A. Lernmark, K.I. Papadopoulos, G. Sundkvist, Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients at diagnosis and following treatment. J. Intern. Med. 239(1), 63–68 (1996). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
61.
E. Kawasaki, N. Abiru, M. Yano, S. Uotani, K. Matsumoto, H. Matsuo, H. Yamasaki, H. Yamamoto, Y. Yamaguchi, S. Akazawa, Autoantibodies in patients with autoimmune thyroid disease: relation to competitive insulin antibodies. J. Autoimmun. 8(5), 633–643 (1995). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1006/​jaut.​1995.​0047 PubMed
62.
D.Y. Aksoy, B.P. Yürekli, B.O. Yildiz, O. Gedik, Prevalence of glutamic acid decarboxylase antibody positivity and its association with insulin secretion and sensitivity in autoimmune thyroid disease: a pilot study. Exp. Clin. Endocrinol. Diabetes 114(8), 412–416 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
63.
M. Pietropaolo, J.C. Hutton, G.S. Eisenbarth, Protein thyrosine phoshatase-like proteins: link with IDDM. Diabetes Care 20(2), 208–214 (1997). (no LoE)PubMed
64.
N.G. Morgenthaler, J. Seissler, P. Achenbach, D. Glawe, M. Payton, H.M. Meinck, M.R. Christie, W.A. Scherbaum, Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or Stiff man syndrome. Autoimmunity 25(4), 203–211 (1997). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
65.
E. Bosi, F. Becker, E. Bonifacio, R. Wagner, P. Collins, E.A. Gale, G. Bottazzo, Progression to type 1 diabetes in autoimmune endocrine patients with islet cell antibodies. Diabetes. 40(8), 977–984 (1991). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
66.
67.
C. Betterle, A.C. Spadaccino, F. Presotto, R. Zanchetta, B. Pedini, M. Lai, N.A. Greggio, G.F. Bottazzo, The number of markers of pancreatic autoimmunity increases the risk for type 1 diabetes mellitus (DM) in Italian and English patients with organ-specific autoimmune diseases (OSAD). Ann. N. Y. Acad. Sci. 958, 276–280 (2002). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
68.
A.R. Radaideh, M.K. Nusier, F.L. Amari, A.E. Bateiha, M.S. El-Khateeb, A.S. Naser, K.M. Ajlouni, Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan. Saudi Med. J. 25(8), 1046–1050 (2004). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
69.
S.A.P. Chubb, W.A. Davis, Z. Inman, T.M. Davis, Prevalence and progression of subclinical hypothyroidism in women with type 2 diabetes: the Fremantle Diabetes Study. Clin. Endocrinol. (Oxford) 62(4), 480–486 (2005). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )
70.
A. Mohn, S. Di Michele, R. Di Luzio, S. Tumini, F. Chiarelli, The effect of subclinical hypothyroidism on metabolic control in children and adolescents with type 1 diabetes mellitus. Diabet. Med. 19(1), 70–73 (2002). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
71.
72.
73.
74.
J.J. Díez, P. Sánchez, P. Iglesias, Prevalence of thyroid dysfunction in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 119(4), 201–207 (2011). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1055/​s-0031-1271691 PubMed
75.
A. Huber, F. Menconi, S. Corathers, E.M. Jacobson, Y. Tomer, Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr. Rev. 29(6), 697–725 (2008). doi:10.​1210/​er.​2008-0015. (no LoE)PubMedCentralPubMed
76.
E.C. Somers, S.L. Thomas, L. Smeeth, A.J. Hall, Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology 17(2), 202–217 (2006). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
77.
P.R. Gallas, R.P. Stolk, K. Bakker, E. Endert, W.M. Wiersinga, Thyroid dysfunction during pregnancy and in the first postpartum year in women with diabetes mellitus type 1. Eur. J. Endocrinol. 147(4), 443–451 (2002). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
78.
A. Hanukoglu, A. Mizrachi, I. Dalal, O. Admoni, Y. Rakover, Z. Bistritzer, A. Levine, E. Somekh, D. Lehmann, M. Tuval, M. Boaz, A. Golander, Extrapancreatic autoimmune manifestations in type 1 diabetes patients and their first-degree relatives: a multicenter study. Diabetes Care. 26(4), 1235–1240 (2003). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
79.
G.C. Gonzàles, I. Capel, J. Rodríguez-Espinosa, D. Mauricio, A. de Leiva, A. Pérez, Thyroid autoimmunity at onset of type 1 diabetes as a predictor of thyroid dysfunction. Diabetes Care 30(6), 1611–1612 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
80.
O. Kordonouri, D. Deiss, T. Danne, A. Dorow, C. Bassir, A. Grüters-Kieslich, Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with type 1 diabetes. Diabet. Med. 19(6), 518–521 (2002). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
81.
O. Kordonouri, R. Hartmann, D. Deiss, M. Wilms, A. Grüters-Kieslich, Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch. Dis. Child. 90(4), 411–414 (2005). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMedCentralPubMed
82.
B. Lindberg, U.B. Ericsson, R. Ljung, S.A. Ivarsson, High prevalence of thyroid autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children. J. Lab. Clin. Med. 130(6), 585–589 (1997). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
83.
M.J.B. Villano, A.K. Huber, D.A. Greenberg, B.K. Golden, E. Concepcion, Y. Tomer, Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohort of multiplex families. J. Clin. Endocrinol. Metab. 94(4), 1458–1466 (2009). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif ) doi:10.​1210/​jc.​2008-2193 PubMedCentralPubMed
84.
85.
A. Van den Driessche, V. Eenkhoorn, L. Van Gaal, C. De Block, Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth. J. Med. 67(11), 376–387 (2009). (no LoE)PubMed
86.
J.M. Barker, Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J. Clin. Endocrinol. Metab. 91(4), 1210–1217 (2006). (no LoE)PubMed
87.
G.S. Eisenbarth, P.A. Gottlieb, Autoimmune polyendocrine syndromes. N. Engl. J. Med. 350(20), 2068–2079 (2004). (no LoE)PubMed
88.
American Diabetes Association, Standards of Medical Care in Diabetes 2012. Diabetes Care 35(Suppl 1), S11–S63 (2012). doi:10.​2337/​dc12-s011. (no LoE)
89.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diabetes 37(suppl 1), S1–S212 (2013). doi:10.​1016/​j.​jcjd.​2013.​01.​009. (no LoE)
90.
J.M. Dora, W.E. Machado, J. Rheinheimer, D. Crispim, A.L. Maia, Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur. J. Endocrinol. 163(3), 427–434 (2010). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1530/​EJE-10-0419 PubMed
91.
H.R. Maxon, K.W. Kreines, R.E. Goldsmith, H.C. Knowles Jr, Long-term observations of glucose tolerance in thyrotoxic patients. Arch. Intern. Med. 135(11), 1477–1480 (1975). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
92.
93.
P. Cavallo-Perin, A. Bruno, L. Boine, M. Cassader, G. Lenti, G. Pagano, Insulin resistance in Graves’ disease: a quantitative in vivo evaluation. Eur. J. Clin. Invest. 18(6), 607–613 (1988). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
94.
E. Maratou, D.J. Hadjidakis, M. Peppa, M. Alevizaki, K. Tsegka, V. Lambadiari, P. Mitrou, E. Boutati, A. Kollias, T. Economopoulos, S.A. Raptis, G. Dimitriadis, Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur. J. Endocrinol. 163(4), 625–630 (2010). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )doi:10.​1530/​EJE-10-0246 PubMed
95.
P. Mitrou, E. Boutati, V. Lambadiari, A. Tsegka, A.E. Raptis, N. Tountas, T. Economopoulos, S.A. Raptis, G. Dimitriadis, Insulin resistance in hyperthyroidism: the role of IL6 and TNF alpha. Eur. J. Endocrinol. 162(1), 121–126 (2010). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1530/​EJE-09-0622 PubMed
96.
A. Bhattacharyya, P.G. Wiles, Diabetic ketoacidosis precipitated by thyrotoxicosis. Postgrad. Med. J. 75(883), 291–292 (1999). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMedCentralPubMed
97.
K.A. Al-Shoumer, B.A. Vasanthy, M.M. Al-Zaid, Effects of treatment of hyperthyroidism on glucose homeostasis, insulin secretion, and markers of bone turnover. Endocr. Pract. 12(2), 121–130 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
98.
E. Solà, C. Morillas, S. Garzón, M. Gómez-Balaguer, A. Hernández-Mijares, Association between diabetic ketoacidosis and thyrotoxicosis. Acta. Diabetol. 39(4), 235–237 (2002). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
99.
M. Kunishige, E. Sekimoto, M. Komatsu, Y. Bando, H. Uehara, K. Izumi, Thyrotoxicosis masked by diabetic ketoacidosis: a fatal complication. Diabetes Care 24(1), 171 (2001). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
100.
R. Naeije, J. Golstein, N. Clumeck, H. Meinhold, K.W. Wenzel, L. Vanhaelst, A low T3 syndrome in diabetic ketoacidosis. Clin. Endocrinol. (Oxford) 8(6), 467–472 (1978). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
101.
K.K. Boelaert, J.A. Franklyn, Thyroid hormone in health and disease. J. Endocrinol. 187(1), 1–15 (2005). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
102.
J.A. Franklin, P. Maisonneuve, M.C. Sheppard, J. Betteridge, P. Boyle, Mortality after the treatment of hyperthyroidism with radioactive iodine. N. Engl. J. Med. 338(11), 712–718 (1998). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
103.
S.W. Moon, J.R. Hahm, G.W. Lee, M.Y. Kang, J.H. Jung, T.S. Jung, K.W. Lee, K.A. Jung, Y.J. Ahn, S. Kim, M.A. Kim, D.R. Kim, S.I. Chung, M.H. Park, A case of hyperglycemic hyperosmolar state associated with Graves’ hyperthyroidism: a case report. J. Korean Med. Sci. 21(4), 765–767 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMedCentralPubMed
104.
M.F. Celani, M.E. Bonati, N. Stucci, Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus. Diabetes Res. 27(1), 15–25 (1994). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
105.
E. Maratou, D.J. Hadjidakis, A. Kollias, K. Tsegka, M. Peppa, M. Alevizaki, P. Mitrou, V. Lambadiari, E. Boutati, D. Nikzas, N. Tountas, T. Economopoulos, S.A. Raptis, G. Dimitriadis, Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur. J. Endocrinol. 160(5), 785–790 (2009). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1530/​EJE-08-0797 PubMed
106.
107.
H. Debiec, H.S. Cross, M. Peterlik, d-glucose uptake is increased in jejunal brush-border membrane vesicles from hyperthyroid chicks. Acta. Endocrinol. (Copenh) 120(4), 435–441 (1989). (no LoE)
108.
A.R. Cappola, P.W. Ladenson, Hypothyroidism and atherosclerosis. J. Clin. Endocrinol. Metab. 88(6), 2438–2444 (2003). (no LoE)PubMed
109.
L. Duntas, G. Kolovou, Options for the treatment of hyperlipidemia in type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Future Cardiol. 7(2), 137–144 (2011). doi:10.​2217/​fca.​10.​126. (no LoE)PubMed
110.
E. Yeter, T. Keles, T. Durmaz, E. Bozkurt, Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report. J. Med. Case Rep. 1, 130 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMedCentralPubMed
111.
K. Tokinaga, T. Oeda, Y. Suzuki, Y. Matsushima, HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr. J. 53(3), 401–405 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
112.
M.P. Vanderpump, W.M. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, J. Grimley Evans, H. Rodgers, F. Tunbridge, E.T. Youn, The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 6(3), 155–160 (1996). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
113.
S.A. Chubb, W.A. Davis, T.M. Davis, Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study. J. Clin. Endocrinol. Metab. 90(9), 5317–5320 (2005). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
114.
115.
N. Knudsen, P. Laurberg, L.B. Rasmussen, I. Bülow, H. Perrild, L. Ovesen, T. Jørgensen, Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J. Clin. Endocrinol. Metab. 90(7), 4019–4024 (2005). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
116.
N. Manji, K. Boelaert, M.C. Sheppard, R.L. Holder, S.C. Gough, J.A. Franklyn, Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin. Endocrinol. (Oxford) 64(2), 125–128 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
117.
K. Oboubie, J. Smith, L.M. Evans, R. John, J.S. Davies, J.H. Lazarus, Increased central arterial stiffness in hypothyroidism. J. Clin. Endocrinol. Metab. 87(10), 4662–4666 (2002). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
118.
P.J. Owen, R. Sabit, J.H. Lazarus, Thyroid disease and vascular function. Thyroid 17, 519–524 (2007)PubMed
119.
R.S. Gray, D.Q. Borsey, W.J. Irvine, J. Seth, B.F. Clarke, Natural history of thyroid function in diabetics with impaired thyroid reserve: a four year controlled study. Clin. Endocrinol. (Oxford) 19(4), 445–451 (1983). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )
120.
A. Franzese, P. Buono, M. Mascolo, A.L. Leo, G. Valerio, Thyroid autoimmunity starting during the course of type 1 diabetes denotes a subgroup of children with more severe diabetes. Diabetes Care 23(8), 1201–1202 (2000). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
121.
T. Sathyapalan, A.M. Manuchehri, A.S. Rigby, S.L. Atkin, Subclinical hypothyroidism is associated with reduced all-cause mortality in patients with type 2 diabetes. Diabetes Care 33(3), e37 (2010). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif ) doi:10.​2337/​dc09-1555 PubMed
122.
A.E. Hak, H.A. Pols, T.J. Visser, H.A. Drexhage, A. Hofman, J.C. Witteman, Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann. Intern. Med. 132(4), 270–278 (2000). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
123.
M.D. Danese, P.W. Ladenson, C.L. Meinert, N.R. Powe, Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J. Clin. Endocrinol. Metab. 85(9), 2993–3001 (2000). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figd_HTML.gif )PubMed
124.
H.S. Chen, T.E. Wu, T.S. Jap, R.A. Lu, M.L. Wang, R.L. Chen, H.D. Lin, Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in type 2 diabetic patients. Diabet. Med. 24(12), 1336–1344 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
125.
A.I. Katz, D.S. Emmanouel, M.D. Lindheimer, Thyroid hormone and the kidney. Nephron 15(3–5), 223–249 (1975). (no LoE)PubMed
126.
J.K. Yang, W. Liu, J. Shi, Y.B. Li, An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients. Diabetes Care 33(5), 1018–1020 (2010). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​2337/​dc09-1784 PubMedCentralPubMed
127.
G.R. Yang, J.K. Yang, L. Zhang, Y.H. An, J.K. Lu, Association between subclinical hypothyroidism and proliferative diabetic retinopathy in type 2 diabetic patients: a case-control study. Tohoku J. Exp. Med. 222(4), 303–310 (2010). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif )PubMed
128.
R.G. Tilton, G. Pugliese, K. Chang, A. Speedy, M.A. Province, C. Kilo, J.R. Williamson, Effects of hypothyroidism on vascular 125I-albumin permeation and blood flow in rats. Metabolism 38(5), 471–478 (1989). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
129.
S. Taddei, N. Caraccio, A. Virdis, A. Dardano, D. Versari, L. Ghiadoni, A. Salvetti, E. Ferrannini, F. Monzani, Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J. Clin. Endocrinol. Metab. 88(8), 3731–3737 (2003). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
130.
L. Mutapcic, S.M. Wren, D.A. Leske, M.P. Fautsch, J.M. Holmes, The effect of l-thyroxine supplementation on retinal vascular development in neonatal rats. Curr. Eye Res. 30(12), 1035–1040 (2005). (no LoE)PubMed
131.
K.A. Toulis, A. Stagnaro-Green, R. Negro, Maternal subclinical hypothyroidism and gestational diabetes mellitus: a meta analysis. Endocr. Pract. 20(7), 703–714 (2014). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​4158/​EP13440.​RA PubMed
132.
H.C. Gerstein, Incidence of postpartum thyroid dysfunction in patients with type 1 diabetes mellitus. Ann. Intern. Med. 118(6), 419–423 (1993). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
133.
M. Vestgaard, L.R. Nielsen, A.K. Rasmussen, P. Damm, E.R. Mathiesen, Thyroid peroxidase antibodies in pregnant women with type 1 diabetes: impact on thyroid function, metabolic control and pregnancy outcome. Acta Obstet. Gynecol. Scand. 87(12), 1336–1342 (2008). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1080/​0001634080249926​1 PubMed
134.
A. Stagnaro-Green, Clinical review 152: postpartum thyroiditis. J. Clin. Endocrinol. Metab. 87(9), 4042–4047 (2002). (no LoE)PubMed
135.
P. Karakosta, D. Alegakis, V. Georgiou, T. Roumeliotaki, E. Fthenou, M. Vassilaki, D. Boumpas, E. Castanas, M. Kogevinas, L. Chatzi, Thyroid dysfunction and autoantibodies in early pregnancy are associated with increased risk of gestational diabetes and adverse birth outcomes. J. Clin. Endocrinol. Metab. 97(12), 4464–4472 (2012). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif ) doi:10.​1210/​jc.​2012-2540 PubMed
136.
L. De Groot, M. Abalovich, E.K. Alexander, N. Amino, L. Barbour, R.H. Cobin, C.J. Eastman, J.H. Lazarus, D. Luton, S.J. Mandel, J. Mestman, J. Rovet, S. Sullivan, Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 97(8), 2543–2565 (2012). doi:10.​1210/​jc.​2011-2803. (no LoE)PubMed
137.
M.J. McKenna, R. Herskowitz, J.I. Wolfsdorf, Screening for thyroid disease in children with IDDM. Diabetes Care 13(7), 801–803 (1990). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
138.
R. Junik, M. Kozinski, K. Debska-Kozinska, Thyroid ultrasound in diabetic patients without overt thyroid disease. Acta. Radiol. 47(7), 687–691 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
139.
J.J. Díez, P. Iglesias, An analysis of the relative risk for goitre in euthyroid patients with type 2 diabetes. Clin. Endocrinol. (Oxford) 80(3), 356–361 (2014). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1111/​cen.​12169
140.
C.M. Kitahara, E.A. Platz, L.E. Beane Freeman, A. Black, A.W. Hsing, M.S. Linet, Y. Park, C. Schairer, A. Berrington de González, Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies (2012). Cancer Causes Control 23, 463–471 (2012). (Loe https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figc_HTML.gif ) doi:10.​1007/​s10552-012-9896-y
141.
142.
143.
D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin, B. Zinman, American Diabetes Association, European Association for the Study of Diabetes, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52(1), 17–30 (2009). doi:10.​1007/​s00125-008-1157-y PubMed
144.
R.A. Vigersky, A. Filmore-Nassar, A.R. Glass, Thyrotropin suppression by metformin. J. Clin. Endocrinol. Metab. 91(1), 225–227 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
145.
M.L. Isidro, M.A. Penín, R. Nemiña, F. Cordido, Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 32(1), 79–82 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
146.
C. Cappelli, M. Rotondi, I. Pirola, B. Agosti, E. Gandossi, U. Valentini, E. De Martino, A. Cimino, L. Chiovato, E. Agabiti-Rosei, M. Castellano, TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on l-T4 therapy patients. Diabetes Care 32(9), 1589–1590 (2009). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​2337/​dc09-0273 PubMedCentralPubMed
147.
J.J. Díez, P. Iglesias, Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin. Endocrinol. (Oxford) 78(4), 505–511 (2013). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1111/​j.​1365-2265.​2012.​04468.​x
148.
J. Klubo-Gwiezdzinska, J. Costello Jr, A. Patel, A. Bauer, K. Jensen, M. Mete, K.D. Burman, L. Wartofsky, V. Vasko, Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J. Clin. Endocrinol. Metab. 98(8), 3269–3279 (2013). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif ) doi:10.​1210/​jc.​2012-3799 PubMed
149.
R.E. Tranquada, D.H. Solomon, J. Brown, R. Greene, The effect of oral hypoglycemic agents on thyroid function in the rat. Endocrinology. 67, 293–297 (1960). (no LoE)PubMed
150.
J.M. Hershman, T.J. Craane, J.A. Colwell, Effect of sulfonylurea drugs on the binding of triiodothyronine and thyroxine to thyroxine-binding globulin. J. Clin. Endocrinol. Metab. 28(11), 1605–1610 (1968). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
151.
C. Kilo, J. Dudley, B. Kalb, Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. Diabetes Res. Clin. Pract. 14(Suppl 2), S79–S82 (1991). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
152.
M.L. England, J.M. Hartnell, J.M. Hershman, S.R. Levin, Glyburide does not alter thyroid function. Diabetes Res. 3(9), 471–474 (1986). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
153.
S.W. Shen, R. Bressler, Clinical pharmacology of oral antidiabetic agents (second of two parts). N. Engl. J. Med. 296(14), 787–793 (1977). (no LoE)PubMed
154.
B. Efe, E. Entok, E. Güney, E. Erenoğlu, M. Kebapçı, Effects of second generation sulfonylureas on the thyroid. Turk J. Endocrinol. Metab. 4, 173–176 (1999). (no LoE)
155.
K. Starkey, A. Heufelder, G. Baker, W. Joba, M. Evans, S. Davies, M. Ludgate, Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J. Clin. Endocrinol. Metab. 88(1), 55–59 (2003). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
156.
R. Menaka, M. Sehgal, M. Lakshmi, A. Bhattacharyya, Thiazolidinedione precipitated thyroid associated ophthalmopathy. J. Assoc. Physicians India 58, 255–257 (2010). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMed
157.
S. Lee, A. Tsirbas, R.A. Goldberg, J.D. McCann, Thiazolidinedione induced thyroid associated orbitopathy. BMC Ophthalmol. 7, 8 (2007). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figa_HTML.gif )PubMedCentralPubMed
158.
M. Dorkhan, M. Lantz, A. Frid, L. Groop, B. Hallengren, Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin. Endocrinol. (Oxford) 65(1), 35–39 (2006). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )
159.
160.
Byetta (Package insert) Amylin Pharmaceuticals Inc. San Diego (2007) (no LoE)
161.
162.
V.R. Aroda, R. Ratner, The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab. Res. Rev. 27(6), 528–542 (2011). doi:10.​1002/​dmrr.​1202 PubMed
163.
D.J. Drucker, S.I. Sherman, R.M. Bergenstal, J.B. Buse, The safety of incretin-based therapies—review of the scientific evidence. J. Clin. Endocrinol. Metab. 96(7), 2027–2031 (2011). doi:10.​1210/​jc.​2011-0599 PubMed
164.
L. Hegedüs, A.C. Moses, M. Zdravkovic, T. Le Thi, G.H. Daniels, GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J. Clin. Endocrinol. Metab. 96(3), 853–860 (2011). (LoE https://static-content.springer.com/image/art%3A10.1007%2Fs12020-014-0474-9/MediaObjects/12020_2014_474_Figb_HTML.gif )PubMed
165.
166.
167.
M.H. Murad, F. Coto-Yglesias, A.T. Wang, N. Sheidaee, R.J. Mullan, M.B. Elamin, P.J. Erwin, V.M. Montori, Clinical review: drug-induced hypoglycemia: a systematic review. J. Clin. Endocrinol. Metab. 94(3), 741–745 (2009). doi:10.​1210/​jc.​2008-1416 PubMed
Metadata
Title
Italian Association of Clinical Endocrinologists (AME) & Italian Association of Clinical Diabetologists (AMD) Position Statement
Diabetes mellitus and thyroid disorders: recommendations for clinical practice
Authors
Edoardo Guastamacchia
Vincenzo Triggiani
Alberto Aglialoro
Antimo Aiello
Lucia Ianni
Mauro Maccario
Michele Zini
Carlo Giorda
Rinaldo Guglielmi
Corrado Betterle
Roberto Attanasio
Giorgio Borretta
Piernicola Garofalo
Enrico Papini
Roberto Castello
Antonio Ceriello
Publication date
01-06-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0474-9

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue

Endocrine Imaging

Marine-Lenhart Syndrome

Original Article

The associations of bedtime, nocturnal, and daytime sleep duration with bone mineral density in pre- and post-menopausal women

Original Article

A novel function for fibroblast growth factor 21: stimulation of NADPH oxidase-dependent ROS generation

Meta-Analysis

Metabolic syndrome in childhood leukemia survivors: a meta-analysis

Original Article

Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves’ ophthalmopathy

Research Letter

Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits